NYSE:RFL - New York Stock Exchange, Inc. - US75062E1064 - Common Stock - Currency: USD
NYSE:RFL (5/8/2025, 12:19:10 PM)
1.43
-0.03 (-2.05%)
The current stock price of RFL is 1.43 USD. In the past month the price decreased by -13.1%. In the past year, price decreased by -8.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LB | LANDBRIDGE CO LLC-A | 21.26 | 5.56B | ||
VTMX | CORP INMOBILIARIA VESTA-ADR | 8.2 | 2.35B | ||
IRS | IRSA -SP ADR | N/A | 1.07B | ||
KW | KENNEDY-WILSON HOLDINGS INC | N/A | 883.67M | ||
MRNO | MURANO GLOBAL INVESTMENTS PL | N/A | 792.40M | ||
FRPH | FRP HOLDINGS INC | 81.41 | 528.41M | ||
MLP | MAUI LAND & PINEAPPLE CO | N/A | 291.17M | ||
TCI | TRANSCONTINENTAL REALTY INV | 46.96 | 275.88M | ||
SEG | SEAPORT ENTERTAINMENT GROUP | N/A | 251.90M | ||
OZ | BELPOINTE PREP LLC | N/A | 243.16M | ||
RITR | REITAR LOGTECH HOLDINGS LTD | 39.11 | 219.79M | ||
NEN | NEW ENGLAND REALTY ASSOC-LP | 0.58 | 216.30M |
Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-03-12. The firm holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. The company also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. The company holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
RAFAEL HOLDINGS INC-CLASS B
520 Broad Street
Newark NEW JERSEY 07102 US
CEO: Ameet Mallik
Employees: 30
Phone: 12126581450
The current stock price of RFL is 1.43 USD. The price decreased by -2.05% in the last trading session.
The exchange symbol of RAFAEL HOLDINGS INC-CLASS B is RFL and it is listed on the New York Stock Exchange, Inc. exchange.
RFL stock is listed on the New York Stock Exchange, Inc. exchange.
RAFAEL HOLDINGS INC-CLASS B (RFL) has a market capitalization of 45.83M USD. This makes RFL a Nano Cap stock.
RAFAEL HOLDINGS INC-CLASS B (RFL) currently has 30 employees.
RAFAEL HOLDINGS INC-CLASS B (RFL) has a resistance level at 1.61. Check the full technical report for a detailed analysis of RFL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RFL does not pay a dividend.
RAFAEL HOLDINGS INC-CLASS B (RFL) will report earnings on 2025-06-12.
RAFAEL HOLDINGS INC-CLASS B (RFL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.11).
The outstanding short interest for RAFAEL HOLDINGS INC-CLASS B (RFL) is 0.54% of its float. Check the ownership tab for more information on the RFL short interest.
ChartMill assigns a fundamental rating of 2 / 10 to RFL. The financial health of RFL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months RFL reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS decreased by -2619.55% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -60.77% | ||
ROE | -72.74% | ||
Debt/Equity | 0.03 |